Somatropin - BresaGen

Drug Profile

Somatropin - BresaGen

Alternative Names: Human growth hormone - BresaGen

Latest Information Update: 28 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BresaGen
  • Class Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 03 Feb 2004 The directors of BresaGen have resigned and administrators have been appointed
  • 03 Dec 2003 BresaGen plans to commercialise somatropin in collaboration with pharmaceutical partners
  • 11 Jul 2001 Preclinical development for Somatotropin deficiency in Australia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top